MAP3K5 and hepatocellular carcinoma: Therapeutics targeting the signaling pathways involved in fibrogenesis (apoptosis signal-regulating kinase 1, peroxisome proliferator-activated receptors, and chemokine receptor inhibitors) are undergoing clinical trials and may serve as HCC chemoprevention [51].